Institute of Health Informatics, University College London, London, UK.
Royal Free London NHS Foundation Trust, London, UK.
BMJ Open. 2019 Jan 29;9(1):e025664. doi: 10.1136/bmjopen-2018-025664.
Use of albumin therapy is recommended for management of disease complications in cirrhosis. The effectiveness of albumin to prevent specific disease complications and death, however, is less clear.
We will search Medline (Ovid), Embase (Ovid), Cochrane Hepato-Biliary Controlled Trials Register and Cochrane Central Register of Controlled Trials for published reports on randomised controlled trials and observational studies on the effectiveness of intravenous albumin therapy to prevent spontaneous bacterial peritonitis, renal dysfunction and death in cirrhotic patients. Two independent reviewers will screen the studies for eligibility, extract data and assess risk of bias and quality of evidence using Grading of Recommendations Assessment, Development and Evaluation system. Random effects meta-analyses will be performed when appropriate.
As no primary data will be collected, a formal ethical approval is not required. We plan to publish the results of this study in a relevant peer-reviewed journal or journals. The study results may also be presented at relevant conferences and meetings.
CRD42018100798.
白蛋白治疗被推荐用于肝硬化并发症的管理。然而，白蛋白在预防特定疾病并发症和死亡方面的有效性尚不清楚。
我们将在 Medline（Ovid）、Embase（Ovid）、Cochrane 肝胆对照试验登记册和 Cochrane 对照试验中心登记册中搜索关于静脉内白蛋白治疗预防肝硬化患者自发性细菌性腹膜炎、肾功能障碍和死亡的有效性的随机对照试验和观察性研究的已发表报告。两名独立的审查员将筛选研究的合格性，使用推荐评估、制定和评估系统提取数据并评估偏倚风险和证据质量。在适当的情况下，将进行随机效应荟萃分析。
由于不会收集原始数据，因此不需要正式的伦理批准。我们计划在相关同行评审期刊或期刊上发表这项研究的结果。研究结果也可能在相关会议和会议上展示。
CRD42018100798。
